| Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL. | |
| | |
MedLine Citation:
|
PMID: 14675054 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Binding of very low-density lipoprotein (VLDL) isolated from serum of nephrotic rats VLDL to endothelial cells is defective. This defect is conferred on normal VLDL by prior incubation with high-density lipoprotein (HDL) from nephrotic, but not control rats. It is not known whether the defect is present in nascent VLDL (nVLDL) or is acquired after secretion. We test the hypothesis that VLDL is normal at the time of secretion from the liver and the defect in binding to endothelium is conferred following secretion through interaction with HDL. METHODS: nVLDL was synthesized by and collected from isolated perfused livers from either control or nephrotic rats. nVLDL was labeled with 3H-oleate to measure binding and 35S methionine to evaluate apolipoprotein exchange and composition. To test whether HDL conferred a binding defect, nVLDL was incubated with HDL obtained either from control or nephrotic rats prior to measurement of binding. To distinguish the effects of proteinuria from reduced albumin concentration we additionally incubated nVLDL with HDL obtained from rats with hereditary analbuminemia. Both HDL and VLDL were reisolated by centrifugation prior to subsequent binding and lipolysis determination. Exchange of 35S-labeled apolipoprotein E (apoE) among the subsequent VLDL and HDL fractions was determined. To determine the effect of HDL on lipolysis, HDL-treated VLDL was exposed to lipoprotein lipase-coated 96-well plates and 3H-oleate release measured. To establish whether differences in apoE content could explain the differences in binding and lipolysis, apoE was restored to nephrotic VLDL and lipolysis and binding were subsequently measured. RESULTS: Binding of nephrotic nVLDL was greater than control nVLDL (0.58 +/- 0.13 vs. 0.75 +/- 0.07 ng protein bound/mg cell protein) (P= 0.04, N= 6). Lipolysis was similarly elevated (0.091 +/- 0.010 vs 0.064 +/- 0.002 nmol NEFA released/well/hour) (P < 0.05). Prior incubation with nephrotic HDL reduced binding of nVLDL obtained from either nephrotic or control livers (P= 0.02, N= 6). Treatment with nephrotic (vs. control) HDL reduced both binding (control nVLDL + control HDL, 0.64 +/- 0.02; control + nephrotic, 0.43 +/- 0.06; nephrotic + control, 0.69 +/- 0.05; and nephrotic + nephrotic, 0.62 +/- 0.04 mg VLDL protein/mg cell protein) and lipolysis (control nVLDL + control HDL, 0.053 +/- 0.004; control + nephrotic, 0.038 +/- 0.004; nephrotic + control, 0.069 +/- 0.004; and nephrotic + nephrotic, 0.062 +/- 0.004 nmol NEFA/well/hour) (P < 0.05 vs. nVLDL + control HDL) of nVLDL from either source. The apoE content of nVLDL coincubated with control HDL or analbuminemic HDL was increased compared nVLDL incubated with either no HDL or nephrotic HDL (P < 0.05). Similarly, the apoE/apoA-I ratio was reduced in HDL from nephrotic rats but not in HDL from controls (P < 0.05). Reintroduction of apoE to nephrotic VLDL resulted in increased binding. CONCLUSION: Unlike circulating VLDL, binding of nVLDL from isolated livers from nephrotic rats to endothelial cells is greater and its lipolysis is increased compared to control nVLDL. Decreased binding and lipolysis is conferred following incubation with HDL isolated from control, but not nephrotic rats and binding can be restored by reintroduction of apoE. Thus both defects are conferred on VLDL by exposure to HDL obtained from nephrotic animals, possibly a consequence of a failure of nephrotic HDL to enrich VLDL with apoE during clearance. |
| | |
Authors:
|
Gregory C Shearer; William G Couser; George A Kaysen |
Related Documents
:
|
19050314 - The ins (cell) and outs (plasma) of apolipoprotein a-v. 12576514 - Ph6 antigen of yersinia pestis interacts with plasma lipoproteins and cell membranes. 10917154 - Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant... 9316874 - Interactions with human blood in vitro and pharmacokinetic properties in mice of liposo... 9605314 - Motifs and structural fold of the cofactor binding site of human glutamate decarboxylase. 7495724 - Immunological characterization of antigenic domains on human il-2 receptor beta subunit... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Kidney international Volume: 65 ISSN: 0085-2538 ISO Abbreviation: Kidney Int. Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2003-12-16 Completed Date: 2004-09-28 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0323470 Medline TA: Kidney Int Country: United States |
Other Details:
|
Languages: eng Pagination: 228-37 Citation Subset: IM |
Affiliation:
|
Department of Veterans Affairs Northern California Health Care System, Mather, California, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apolipoproteins B / metabolism Apolipoproteins E / pharmacology Cholesterol, HDL / metabolism* Cholesterol, VLDL / chemistry, metabolism*, secretion* Lipolysis Liver / secretion* Nephrotic Syndrome / metabolism* Oleic Acid / metabolism, pharmacology Protein Binding / drug effects, physiology Rats Rats, Sprague-Dawley Structure-Activity Relationship Tritium / diagnostic use |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoproteins B; 0/Apolipoproteins E; 0/Cholesterol, HDL; 0/Cholesterol, VLDL; 10028-17-8/Tritium; 112-80-1/Oleic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: reversal by lifelong antioxidant sup...
Next Document: Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orth...